Elicio Therapeutics Stock Performance
| ELTX Stock | 8.75 0.63 7.76% |
Elicio Therapeutics holds a performance score of 17 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.11, which means not very significant fluctuations relative to the market. As returns on the market increase, Elicio Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Elicio Therapeutics is expected to be smaller as well. Use Elicio Therapeutics semi variance, and the relationship between the sortino ratio and rate of daily change , to analyze future returns on Elicio Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Elicio Therapeutics are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Elicio Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 7.76 | Five Day Return 10.62 | Year To Date Return 70.23 | Ten Year Return 48.56 | All Time Return 48.56 |
Last Split Factor 1:10 | Last Split Date 2023-06-02 |
1 | Elicio Therapeutics Secures FDA Support for ELI-002 Cancer Therapy Phase 3 Strategy - StockTitan | 01/22/2025 |
2 | Elicio Therapeutics secures 10 million in direct offering - Investing.com | 01/30/2025 |
3 | Acquisition by Robert Connelly of 121600 shares of Elicio Therapeutics at 8.92 subject to Rule 16b-3 | 02/03/2025 |
4 | Why Elicio Therapeutics Inc Is Skyrocketing So Far In 2025 | 02/04/2025 |
5 | How to Take Advantage of moves in - Stock Traders Daily | 02/13/2025 |
6 | Acquisition by Peter DeMuth of 44400 shares of Elicio Therapeutics at 8.92 subject to Rule 16b-3 | 02/21/2025 |
7 | Disposition of 3442341 shares by Chudnovsky Yekaterina of Elicio Therapeutics at 5.81 subject to Rule 16b-3 | 03/05/2025 |
| Begin Period Cash Flow | 8.4 M |
Elicio |
Elicio Therapeutics Relative Risk vs. Return Landscape
If you would invest 503.00 in Elicio Therapeutics on December 23, 2024 and sell it today you would earn a total of 372.00 from holding Elicio Therapeutics or generate 73.96% return on investment over 90 days. Elicio Therapeutics is currently generating 1.0128% in daily expected returns and assumes 4.5987% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Elicio, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Elicio Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Elicio Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Elicio Therapeutics, and traders can use it to determine the average amount a Elicio Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2202
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ELTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.6 actual daily | 41 59% of assets are more volatile |
Expected Return
| 1.01 actual daily | 20 80% of assets have higher returns |
Risk-Adjusted Return
| 0.22 actual daily | 17 83% of assets perform better |
Based on monthly moving average Elicio Therapeutics is performing at about 17% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Elicio Therapeutics by adding it to a well-diversified portfolio.
Elicio Therapeutics Fundamentals Growth
Elicio Stock prices reflect investors' perceptions of the future prospects and financial health of Elicio Therapeutics, and Elicio Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Elicio Stock performance.
| Return On Equity | -3.53 | ||||
| Return On Asset | -0.74 | ||||
| Current Valuation | 137.79 M | ||||
| Shares Outstanding | 15.86 M | ||||
| Price To Book | 10.11 X | ||||
| EBITDA | (32.97 M) | ||||
| Net Income | (35.2 M) | ||||
| Total Debt | 6.92 M | ||||
| Book Value Per Share | (1.76) X | ||||
| Cash Flow From Operations | (32.69 M) | ||||
| Earnings Per Share | (3.44) X | ||||
| Market Capitalization | 138.79 M | ||||
| Total Asset | 27.15 M | ||||
| Retained Earnings | (142.2 M) | ||||
| Working Capital | 6.58 M | ||||
About Elicio Therapeutics Performance
Evaluating Elicio Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Elicio Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Elicio Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 64.27 | 67.49 | |
| Return On Tangible Assets | (1.49) | (1.57) | |
| Return On Capital Employed | (1.85) | (1.76) | |
| Return On Assets | (1.49) | (1.57) | |
| Return On Equity | (3.56) | (3.38) |
Things to note about Elicio Therapeutics performance evaluation
Checking the ongoing alerts about Elicio Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Elicio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Elicio Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (35.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Elicio Therapeutics generates negative cash flow from operations | |
| About 44.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 3442341 shares by Chudnovsky Yekaterina of Elicio Therapeutics at 5.81 subject to Rule 16b-3 |
- Analyzing Elicio Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Elicio Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Elicio Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Elicio Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Elicio Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Elicio Therapeutics' stock. These opinions can provide insight into Elicio Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.